|
 |
 |
 |
 |
 |
 |
- Home
- Join or Change Subscription
- GSI Community
- For New Patients
- About GIST
- Pediatric GIST & Carney Triad
- Treatments
- Ask the Professional
- Learning Center
- Voices of GIST
- Educational Materials
- GIST Support Wiki
- Donate
Sorafenib plus temsirolimus
 | |
 | |
Sorafenib plus Temsirolimus (CCI-779)
This trial combines a multi-target drug, sorafenib, with an mTOR inhibitor, temsirolimus or CI-779.
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors, NCT00255658
You can read about the trial at this link.
